Is This the Future of Prostate Cancer Screening? How a Simple Saliva Test Could Save Lives

Prostate cancer is the most common cancer in UK men.
Yet, the main screening tool we’ve relied on for decades—the PSA blood test—has well-known limitations. It can miss dangerous cancers, lead to unnecessary procedures, and create confusion for patients and healthcare providers alike.

But now, a groundbreaking new study has suggested there might be a better, smarter way. It’s faster. More accurate. And it starts with something as simple as a saliva sample.

In this post, we’ll walk you through the science behind polygenic risk scores (PRS), highlight the findings of a landmark study published in The New England Journal of Medicine, and explore how Vitall’s at-home Prostate Cancer Risk Test could be the future of early detection.

What Is a Polygenic Risk Score (PRS)?

A polygenic risk score (PRS) estimates an individual’s inherited risk of developing a disease by combining the effects of multiple common genetic variants (single nucleotide polymorphisms or SNPs). In prostate cancer, more than 250 SNPs have now been identified that cumulatively influence disease risk (Eeles et al., 2024).

Rather than looking for a single "faulty gene" like BRCA1, PRS draws on the combined impact of many subtle genetic signals. These variations don’t guarantee you’ll get prostate cancer—but they can indicate if you’re genetically predisposed to developing it.

PSA tells you if something might already be wrong.
PRS tells you how likely you are to develop disease—before symptoms begin.

And best of all? The risk score can be calculated using a simple saliva sample, taken from home.

What the Latest Research Says

A large-scale clinical trial known as BARCODE 1—published in The New England Journal of Medicine in April 2024—evaluated the use of PRS in over 6,000 men aged 55 to 69 of European ancestry. Saliva samples were analysed to assess 130 genetic variants associated with prostate cancer risk.

Men with the highest 10% of PRS scores were invited for further investigation using MRI and biopsy. The results were striking:

• 40% of these men were diagnosed with prostate cancer.
   
• Over 55% of those cancers were clinically significant (Grade Group ≥2)—i.e., aggressive and requiring treatment.
   
• PRS identified more aggressive cancers than PSA or MRI-based screening alone (Eeles et al., 2024).
   

This means that PRS testing not only identifies men at high risk—it finds those with the cancers that are most important to detect early.

PSA vs PRS: What’s the Difference?

PSA testing has long been used but is medically debated, often missing serious cancers or prompting unnecessary procedures. In contrast, PRS testing enables a personalised prevention approach — before symptoms ever appear.

• PSA checks for prostate-specific antigen levels in blood, which fluctuate for many reasons and don’t reflect long-term risk.
• PRS examines your DNA for over 100 markers tied to prostate cancer risk, providing a clearer, lifelong picture — and it can be done from home with a simple saliva test.

As covered by the BBC, DW, and Daily Mail, and The Guardian, this discovery is driving calls for national screening reform.

Vitall offers the UK’s only commercially available Personalised Prostate Cancer PRS Risk Test & Prevention Plan using PRS technology — empowering men to understand their risk and act early.

This is prevention, personalised. Only available in the UK via Vitall.

Traditional PSA tests are known to have poor specificity, with many men undergoing unnecessary biopsies due to transient PSA elevations not caused by cancer (Loeb et al., 2014). Moreover, PSA often fails to detect aggressive forms of the disease in time.

In contrast, PRS allows clinicians to stratify individuals into low-, medium-, or high-risk groups before cancer develops, enabling smarter decisions about who should be monitored more closely or tested further (Mars et al., 2020).

Why It Matters Here in the UK

Let’s look at the facts:

• 1 in 8 UK men will be diagnosed with prostate cancer in their lifetime (Cancer Research UK, 2023).
   
• It is the second leading cause of cancer-related death in UK men, after lung cancer.
   
• NHS screening guidelines still rely largely on PSA testing and symptom presentation.
   

However, recent analysis from the Institute of Cancer Research (ICR) found that integrating PRS testing into routine care could prevent up to 20% more deaths and save the NHS over £500 million annually by reducing overtreatment and unnecessary investigations (ICR, 2024).

The UK's Only At-Home Prostate Cancer PRS Test — Available from Vitall

At Vitall, we’re proud to offer the UK’s only at-home saliva test for prostate cancer risk using validated polygenic risk scoring.

Here’s how it works:

✅ Collect your saliva sample at home.
✅ Send it to our UK-based, NHS-trusted lab.
✅ Receive secure, personalised results within days.

Whether you have a family history of prostate cancer or simply want clarity around your personal risk, this test empowers you to take action early.

Why Early Risk Assessment Matters

When detected early, prostate cancer has a 98–100% 10-year survival rate. But once it spreads, survival drops dramatically (Cancer Research UK, 2023). Most aggressive cancers are asymptomatic until late stages.

PRS testing enables individuals to understand their inherited risk decades earlier, making it easier to:

• Monitor proactively
   
• Make lifestyle changes
   
• Decide when (and if) additional testing is necessary
   

This is precision medicine in action.

Ready to Take Control of Your Risk?

Explore Vitall’s Prostate Cancer Risk Home Test Kit—the UK's only at-home saliva-based genetic screening test assessing polygenic risk for prostate cancer.

👉 Order Your Test Here

Because knowing your risk isn't about fear—it’s about freedom.

The freedom to act. The freedom to plan. The freedom to protect your future.